A Trial Evaluating the Activity and Safety of Combination Between Cabozantinib and Temozolomide in Lung and GEP-NENS Progressive After Everolimus, Sunitinib or PRRT (CABOTEM)

NCT04893785 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

35

Enrollment

OTHER

Sponsor class

Conditions

Lung Neuroendocrine Neoplasm
GEP Neuroendocrine Tumor

Interventions

DRUG: Cabozantinib and Temozolomide

Sponsor

National Cancer Institute, Naples